A Systems View Across Time and Space
Table 1 TAM, and SAM for hypertension, blood thinning, insulin-related and non-insulin-related drugs. Figures presented are annual values
| Â | USA | Europe | APAC |
|---|---|---|---|
Anti-hypertension drugs TAM: $33bn | |||
SAM market share | 40% | 20% | 23% |
SAM value | $13.2bn | $6.6bn | $7.59bn |
Anti-coagulant drugs TAM: $25bn | |||
SAM market share | 40% | 30% | 24% |
SAM value | $10bn | $7.5bn | $6bn |
Insulin-related drugs TAM: $42bn | |||
SAM market share | 40% | 20% | 30% |
SAM value | $16.8bn | $8.4bn | $12.6bn |
Non-insulin-related drugs TAM: $27bn | |||
SAM market share | 38% | 20% | 28% |
SAM value | $10.26bn | $5.4bn | $7.56bn |